Company news
Cytomed Therapeutics Limited (NASDAQ:GDTC) news
Cytomed Therapeutics Limited news releases on 6ix. Latest, May 6, 2026: CytoMed Therapeutics : Audited Financial Statements for FY2025
Press releases & updates
CytoMed Therapeutics : Audited Financial Statements for FY2025
May 6, 2026
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
January 28, 2026
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital
January 13, 2026
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia
December 8, 2025
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
November 18, 2025
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy
November 6, 2025
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%
October 22, 2025
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
October 14, 2025
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
October 2, 2025
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
October 1, 2025
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
August 28, 2025
CytoMed Therapeutics Limited Announces At-the-Market Offering Program
August 19, 2025
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
August 17, 2025
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
July 21, 2025
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
April 28, 2025
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
February 5, 2025
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical tr...
January 5, 2025
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
November 19, 2024
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
October 6, 2024
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
October 2, 2024
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
September 29, 2024
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
July 16, 2024
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
March 19, 2024
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
March 17, 2024
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
March 3, 2024
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
January 28, 2024
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
December 4, 2023
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
November 16, 2023
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
November 13, 2023
CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
October 23, 2023
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
September 24, 2023
CytoMed Expands Research Collaboration into China After Entering Into MOU
August 28, 2023
CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit
August 16, 2023
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency
August 14, 2023
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
July 31, 2023
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
July 5, 2023
CytoMed Therapeutics to Ring Nasdaq Closing Bell
May 10, 2023
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
May 8, 2023
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering
April 12, 2023